Insights on SKIPPirr Data: Exploring Amivantamab in Action

A panelist discusses how EGFR-mutated NSCLC treatment has evolved to include multiple generations of EGFR tyrosine kinase inhibitors as first-line therapy, with newer agents showing improved efficacy compared with earlier options.

A panelist discusses how infusion-related reactions to monoclonal antibodies in EGFR-mutated NSCLC can be effectively managed through preventive measures demonstrated in the phase 2 SKIPPirr trial.